Have a feature idea you'd love to see implemented?
Let us know!
CPIX Cumberland Pharmaceuticals Inc
Price (delayed)
$1.27
Market cap
$17.9M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.73
Enterprise value
$22.13M
Cumberland Emerging Technologies, Inc.(www.cet-fund.com)is a joint initiative between Cumberland Pharmaceuticals Inc., Vanderbilt University, LaunchTN and WinHealth Pharma. The mission of CET is to bring biomedical technologies and products conceived at
Highlights
The quick ratio has increased by 6% QoQ and by 3.5% YoY
CPIX's equity is down by 29% year-on-year and by 4.1% since the previous quarter
Cumberland Pharmaceuticals's EPS has decreased by 24% from the previous quarter
Key stats
What are the main financial stats of CPIX
Market
Valuations
Earnings
Shares outstanding
14.1M
Market cap
$17.9M
Enterprise value
$22.13M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.68
Price to sales (P/S)
0.47
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.59
Revenue
$37.79M
EBIT
-$9.79M
EBITDA
-$3.61M
Free cash flow
-$1M
Per share
Balance sheet
Liquidity
EPS
-$0.73
Free cash flow per share
-$0.07
Book value per share
$1.86
Revenue per share
$2.68
TBVPS
$4.05
Total assets
$78.52M
Total liabilities
$52.49M
Debt
$21.57M
Equity
$26.35M
Working capital
$10.82M
Debt to equity
0.82
Current ratio
1.44
Quick ratio
1.17
Net debt/EBITDA
-1.17
Margins
Efficiency
Dividend
EBITDA margin
-9.6%
Gross margin
82.6%
Net margin
-27.5%
Operating margin
-29%
Return on assets
-12.6%
Return on equity
-34.7%
Return on invested capital
-28.9%
Return on capital employed
-18.2%
Return on sales
-25.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CPIX stock price
How has the Cumberland Pharmaceuticals stock price performed over time
Intraday
-3.79%
1 week
2.42%
1 month
-1.55%
1 year
-38.65%
YTD
-29.05%
QTD
-0.78%
Financial performance
How have Cumberland Pharmaceuticals's revenue and profit performed over time
Revenue
$37.79M
Gross profit
$31.2M
Operating income
-$10.94M
Net income
-$10.38M
Gross margin
82.6%
Net margin
-27.5%
The company's operating margin has shrunk by 190% YoY and by 14% QoQ
CPIX's operating income has dropped by 168% year-on-year and by 11% since the previous quarter
The company's net margin fell by 27% QoQ
The net income fell by 23% QoQ
Growth
What is Cumberland Pharmaceuticals's growth rate over time
Valuation
What is Cumberland Pharmaceuticals stock price valuation
P/E
N/A
P/B
0.68
P/S
0.47
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.59
Cumberland Pharmaceuticals's EPS has decreased by 24% from the previous quarter
CPIX's P/B is 32% below its 5-year quarterly average of 1.0 and 15% below its last 4 quarters average of 0.8
CPIX's equity is down by 29% year-on-year and by 4.1% since the previous quarter
The stock's price to sales (P/S) is 57% less than its 5-year quarterly average of 1.1 and 22% less than its last 4 quarters average of 0.6
The revenue has contracted by 7% YoY and by 2.7% from the previous quarter
Efficiency
How efficient is Cumberland Pharmaceuticals business performance
The company's return on equity fell by 34% QoQ
Cumberland Pharmaceuticals's ROS has decreased by 30% from the previous quarter
The ROA has contracted by 27% from the previous quarter
CPIX's return on invested capital is down by 24% since the previous quarter
Dividends
What is CPIX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CPIX.
Financial health
How did Cumberland Pharmaceuticals financials performed over time
The total assets is 50% greater than the total liabilities
The total assets has declined by 12% year-on-year and by 3.7% since the previous quarter
The current ratio is down by 11% year-on-year but it is up by 5% since the previous quarter
The company's debt is 18% lower than its equity
The debt to equity has soared by 61% YoY and by 3.8% from the previous quarter
CPIX's equity is down by 29% year-on-year and by 4.1% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.